Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

IMMUNOCYTOCHEMICAL DEMONSTRATION OF S-PHASE CELLS BY ANTI-BROMODEOXYURIDINE MONOCLONAL-ANTIBODY IN HUMAN-BRAIN TUMOR-TISSUES ACTA NEUROPATHOLOGICA Nagashima, T., DeArmond, S. J., Murovic, J., Hoshino, T. 1985; 67 (1-2): 155-159

Abstract

Five patients with various brain tumors received bromodeoxyuridine (BrdU), 150-200 mg/m2 i.v., at the time of craniotomy. Biopsied materials were fixed in 70% ethanol, sectioned, denatured with hydrochloric acid, and reacted with monoclonal antibodies against BrdU. Immunofluorescence and immunocytochemical methods were used to visualize BrdU-labeled nuclei. Our results showed that both methods demonstrated BrdU-labeled nuclei satisfactorily in tissue sections. Thus, BrdU can be used to measure the proliferative potential of human tumors in situ.

View details for Web of Science ID A1985AKG5200019

View details for PubMedID 2992212